C4 Therapeutics, Inc. Right-of-Use Asset Obtained in Exchange for Operating Lease Liability
C4 Therapeutics, Inc. (CCCC) reported Right-of-Use Asset Obtained in Exchange for Operating Lease Liability of $0 for the 12-month period ending 2023-12-31, per its 10-K filed 2024-02-22.
Discontinued › Notes › Leases
us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability · last filed 2024-02-22
- C4 Therapeutics, Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2023-12-31 was $0.00.
- C4 Therapeutics, Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2023-09-30 was $0.00.
- C4 Therapeutics, Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2023-06-30 was $0.00.
- C4 Therapeutics, Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2023-03-31 was $0.00, a 100.00% decline year-over-year.
- C4 Therapeutics, Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- C4 Therapeutics, Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2022 was $44.07M, a 118.90% increase from fiscal 2021.
- C4 Therapeutics, Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2021 was $20.13M.
| Period end | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 3 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 6 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 9 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $0.00 derived: sum of 2 quarters · filed 2024-02-22 | $0.00 derived: sum of 3 quarters · filed 2024-02-22 | $0.00 10-K · filed 2024-02-22 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-01 | $0.00 derived: sum of 2 quarters · filed 2023-11-01 | $0.00 10-Q · filed 2023-11-01 | $0.00 derived: sum of 4 quarters · filed 2024-02-22 |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $0.00 10-Q · filed 2023-08-08 | $0.00 derived: sum of 3 quarters · filed 2024-02-22 | $0.00 derived: sum of 4 quarters · filed 2024-02-22 |
| 2023-03-31 | $0.00 10-Q · filed 2023-05-04 | $0.00 derived: sum of 2 quarters · filed 2024-02-22 | $0.00 derived: sum of 3 quarters · filed 2024-02-22 | $0.00 derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $0.00 derived: sum of 2 quarters · filed 2024-02-22 | $0.00 derived: sum of 3 quarters · filed 2024-02-22 | $44.07M 10-K · filed 2024-02-22 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-01 | $0.00 derived: sum of 2 quarters · filed 2023-11-01 | $44.07M 10-Q · filed 2023-11-01 | $64.20M derived: sum of 4 quarters · filed 2023-11-01 |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $44.07M 10-Q · filed 2023-08-08 | $64.20M derived: sum of 3 quarters · filed 2023-08-08 | $64.20M derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | $44.07M 10-Q · filed 2023-05-04 | $64.20M derived: sum of 2 quarters · filed 2023-05-04 | $64.20M derived: sum of 3 quarters · filed 2023-05-04 | |
| 2021-12-31 | $20.13M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $20.13M derived: sum of 2 quarters · filed 2023-02-23 | $20.13M 10-K · filed 2023-02-23 | |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $0.00 10-Q · filed 2022-11-03 | ||
| 2021-06-30 | $0.00 10-Q · filed 2022-08-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |